Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study

1. Lederman, S.
2. Ottery, F.D.
3. Cano, A.
4. Santoro, N.
5. Shapiro, M.
6. Stute, P.
7. Thurston, R.C.
8. English, M.
9. Franklin, C.
10. Lee, M.
11. Neal-Perry, G.